Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
von Lewinski, D; Kolesnik, E; Wallner, M; Resl, M; Sourij, H.
New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.
Biomed Res Int. 2017; 2017(9):1253425-1253425
Doi: 10.1155/2017/1253425
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kolesnik Ewald
- von Lewinski Dirk
- Co-Autor*innen der Med Uni Graz
- Sourij Harald
- Wallner Markus
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The assessment of the cardiovascular safety profile of any newly developed antihyperglycemic drug is mandatory before registration, as a meta-analysis raised alarm describing a significant increase in myocardial infarction with the thiazolidinedione rosiglitazone. The first results from completed cardiovascular outcome trials are already available: TECOS, SAVOR-TIMI, and EXAMINE investigated dipeptidyl peptidase 4 (DPP-4) inhibitors, ELIXA, LEADER, and SUSTAIN-6 investigated glucagon-like peptide 1 (GLP-1) receptor agonists, and EMPA-REG OUTCOME and CANVAS investigated sodium-dependent glucose transporter 2 (SGLT-2) inhibitors. LEADER, SUSTAIN-6, EMPA-REG OUTCOME, and CANVAS showed potential beneficial results, while the SAVOR-TIMI trial had an increased rate of hospitalization for heart failure. Meanwhile, the same drugs are investigated in preclinical experiments mainly using various animal models, which aim to find interactions and elucidate the underlying downstream mechanisms between the antihyperglycemic drugs and the cardiovascular system. Yet the direct link for observed effects, especially for DPP-4 and SGLT-2 inhibitors, is still unknown. Further inquiry into these mechanisms is crucial for the interpretation of the clinical trials' outcome and, vice versa, the clinical trials provide hints for an involvement of the cardiovascular system. The synopsis of preclinical and clinical data is essential for a detailed understanding of benefits and risks of new antihyperglycemic drugs.
- Find related publications in this database (using NLM MeSH Indexing)
- Clinical Trials as Topic -
- Diabetes Mellitus, Type 2 - complications
- Diabetes Mellitus, Type 2 - drug therapy
- Diabetes Mellitus, Type 2 - pathology
- Heart Failure - chemically induced
- Heart Failure - pathology
- Humans -
- Hypoglycemic Agents - adverse effects
- Hypoglycemic Agents - therapeutic use
- Myocardial Infarction - chemically induced
- Myocardial Infarction - pathology
- Rosiglitazone -
- Sodium-Glucose Transporter 2 Inhibitors -
- Thiazolidinediones - adverse effects
- Thiazolidinediones - therapeutic use